# reload+after+2024-01-22 23:44:41.323557
address1§12278 Scripps Summit Drive
city§San Diego
state§CA
zip§92131
country§United States
phone§858 875 1800
website§https://www.fatetherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
fullTimeEmployees§551
companyOfficers§[{'maxAge': 1, 'name': 'Mr. J. Scott Wolchko', 'age': 53, 'title': 'Founder, CEO, President & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 645000, 'exercisedValue': 3854968, 'unexercisedValue': 1599920}, {'maxAge': 1, 'name': 'Mr. Edward J. Dulac III', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cindy R. Tahl', 'age': 50, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 3890153, 'unexercisedValue': 656415}, {'maxAge': 1, 'name': 'Dr. Bahram  Valamehr Ph.D.', 'age': 46, 'title': 'Chief Research & Development Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 455000, 'exercisedValue': 1390425, 'unexercisedValue': 939510}, {'maxAge': 1, 'name': 'Mr. Jim  Beitel M.B.A.', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jerome  Bressi Ph.D.', 'title': 'Senior Vice President of Regulatory & Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Barbara  Hickingbottom', 'title': 'Senior VP of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.659
priceToSalesTrailing12Months§3.4998498
currency§USD
dateShortInterest§1702598400
forwardEps§-2.03
pegRatio§0.06
exchange§NGM
quoteType§EQUITY
shortName§Fate Therapeutics, Inc.
longName§Fate Therapeutics, Inc.
firstTradeDateEpochUtc§1380634200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§98fe3f7f-5aa9-30d5-b866-ea8a0474dc72
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.0
targetLowPrice§2.0
targetMeanPrice§6.34
targetMedianPrice§5.5
recommendationMean§2.6
recommendationKey§hold
numberOfAnalystOpinions§16
quickRatio§8.523
grossMargins§-1.14636
ebitdaMargins§-1.7758299
trailingPegRatio§None
